Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.73 |
| ▸ | EGLN1 | Q9GZT9 | 18/20 | 0.55 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.55 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.55 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.55 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.55 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27764493 | 0.99 | P4HTM (0.72) | P4HTMEGLN1TET2OGFOD1TET1 | |
| SCHEMBL8182341 | 0.85 | P4HTM (0.72) | P4HTMEGLN1TET2OGFOD1TET1 | |
| Hydrochloric Acid SCHEMBL17938030 | 0.85 | P4HTM (0.62) | P4HTMEGLN1TET2OGFOD1TET1 | |
| SCHEMBL8197743 | 0.85 | P4HTM (1.00) | P4HTMEGLN1 | |
| Hydrochloric Acid SCHEMBL27786207 | 0.84 | P4HTM (0.71) | P4HTMEGLN1TET2OGFOD1TET1 | |
| Hydrochloric Acid SCHEMBL3618381 | 0.84 | P4HTM (0.98) | P4HTMEGLN1 | |
| SCHEMBL3836971 | 0.79 | P4HTM (0.74) | P4HTMEGLN1 | |
| Hydrochloric Acid SCHEMBL17938029 | 0.78 | P4HTM (0.72) | P4HTMEGLN1 | |
| SCHEMBL3706371 | 0.74 | EGLN2 (0.69) | P4HTMEGLN1TET2OGFOD1TET1 | |
| SCHEMBL3594699 | 0.74 | VHL (0.60) | P4HTMEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097404-B1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-07-27 | — | — | EP | disclosed |
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER SCHERRING PHARMA AKTIENGELLSCHAFT (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2008067874-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093803-A1 | SUBSTITUTED DIPYRIDYL-DIHYDROPYRAZOLONES AND USE THEREOF | DCK, THPO, QDPR | P4HTM 412/4885EGLN1 882/4885TET2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.